Nexalin Technology Inc Warrant
NXLIW
NXLIW was delisted on the 19th of September, 2025.
8 hedge funds and large institutions have $155K invested in Nexalin Technology Inc Warrant in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
10.32% more ownership
Funds ownership: 0% → 10.32% (+10%)
8% more capital invested
Capital invested by funds: $143K → $155K (+$11.9K)
0% more funds holding
Funds holding: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$22.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.02K |
| 3 |
CS
Clear Street
New York
|
+$1.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$445 |
NXLIW Hedge Fund Activity: Q4 2022 in Review
8 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Nexalin Technology Inc Warrant (NXLIW) for Q4 2022, worth a combined $155K — up 8.4% from $143K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NXLIW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Warberg Asset Management, adding an estimated $22.7K. The largest seller was UBS Group, cutting an estimated $445.
- 8 institutional investors held Nexalin Technology Inc Warrant (NXLIW) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $155K of Nexalin Technology Inc Warrant stock for Q4 2022, up 8.4% quarter-over-quarter.
- 1 fund opened new Nexalin Technology Inc Warrant positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest Nexalin Technology Inc Warrant buyer in Q4 2022 was Warberg Asset Management, an estimated $22.7K added.
- The largest Nexalin Technology Inc Warrant seller in Q4 2022 was UBS Group, an estimated $445 sold.
Based on aggregated 13F filings for Q4 2022.